User profiles for Laurent Servais
 | Laurent SERVAISUniversity of Oxford Verified email at paediatrics.ox.ac.uk Cited by 13587 |
[HTML][HTML] Nusinersen versus sham control in infantile-onset spinal muscular atrophy
…, CA Chiriboga, K Saito, L Servais… - … England Journal of …, 2017 - Mass Medical Soc
Background Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that
is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an …
is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an …
[HTML][HTML] Risdiplam in type 1 spinal muscular atrophy
…, T Seabrook, P Fontoura, L Servais - … England Journal of …, 2021 - Mass Medical Soc
Background Type 1 spinal muscular atrophy is a rare, progressive neuromuscular disease
that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam is …
that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam is …
[HTML][HTML] Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls
…, RS Scalco, P Fontoura, L Servais - … England Journal of …, 2021 - Mass Medical Soc
Background Type 1 spinal muscular atrophy (SMA) is a progressive neuromuscular disease
characterized by an onset at 6 months of age or younger, an inability to sit without support, …
characterized by an onset at 6 months of age or younger, an inability to sit without support, …
Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives
T Dangouloff, L Servais - Therapeutics and clinical risk …, 2019 - Taylor & Francis
Recent advances in the treatment of spinal muscular atrophy (SMA) have dramatically altered
prognosis. Rather than a rapidly lethal disease, SMA type 1, the most severe form with the …
prognosis. Rather than a rapidly lethal disease, SMA type 1, the most severe form with the …
[HTML][HTML] miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy
Duchenne Muscular Dystrophy (DMD) is a lethal muscle disorder, caused by mutations in the
DMD gene and affects approximately 1:5000–6000 male births. In this report, we identified …
DMD gene and affects approximately 1:5000–6000 male births. In this report, we identified …
Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin
…, B Bader-Meunier, I Kone-Paut, J Sibilia, L Servais… - Medicine, 2014 - journals.lww.com
Necrotizing autoimmune myopathy (NAM) is a group of acquired myopathies characterized
by prominent myofiber necrosis with little or no muscle inflammation. Recently, researchers …
by prominent myofiber necrosis with little or no muscle inflammation. Recently, researchers …
[HTML][HTML] Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
SPR1NT ( NCT03505099 ) was a Phase III, multicenter, single-arm study to investigate the
efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic …
efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic …
[HTML][HTML] Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Most children with biallelic SMN1 deletions and three SMN2 copies develop spinal muscular
atrophy (SMA) type 2. SPR1NT ( NCT03505099 ), a Phase III, multicenter, single-arm trial, …
atrophy (SMA) type 2. SPR1NT ( NCT03505099 ), a Phase III, multicenter, single-arm trial, …
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
Background Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle
deterioration and preferentially affects boys. Antisense-oligonucleotide-induced exon …
deterioration and preferentially affects boys. Antisense-oligonucleotide-induced exon …
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre …
Background Spinal muscular atrophy is a rare, autosomal recessive, neuromuscular disease
caused by biallelic loss of the survival motor neuron 1 (SMN1) gene, resulting in motor …
caused by biallelic loss of the survival motor neuron 1 (SMN1) gene, resulting in motor …